title: [PATHWAY-2 study. Vision of the family physician in the approach of resistant hypertension].
abstract: Resistant hypertension is a relatively prevalent condition in primary care that exceeds 7% of patients with hypertension assisted in the office and that implies a high cardiovascular risk due to its association with cardiovascular events. The PATHWAY-2 study has allowed to establish that spironolactone is the best possible alternative in the fourth line of treatment for most patients. It significantly simplifies the approach of these patients for primary care physicians.
authors.affiliation: C.S. Porto do Son Porto do Son, A Coruña, España. Electronic address: scinzas@semergen.es.
authors.forename: S
authors.initials: S
authors.lastname: Cinza-Sanjurjo
mesh_terms: D017298:Bisoprolol; D018592:Cross-Over Studies; D004311:Double-Blind Method; D017292:Doxazosin; D006801:Humans; D006973:Hypertension; D010821:Physicians, Family; D013148:Spironolactone
chemical_list: D013148:Spironolactone; D017292:Doxazosin; D017298:Bisoprolol
keywords: Atención primaria; Espironolactona; Hipertensión resistente; Primary care; Resistant hypertension; Sprinolactone